Skip to main content
SpringerLink
Log in

Management of Adolescent and Young Adults with Acute Lymphoblastic Leukaemia

  • Chapter
  • First Online:
Pathogenesis and Treatment of Leukemia

  • 471 Accesses

Abstract

Acute Lymphoblastic Leukaemia (ALL) is the commonest malignancy in children and the treatment outcome improved significantly in the past few decades, the 5-year survival increased from 10% to now 90%. The good results of paediatric ALL treatment protocols are also observed in older children in large multicenter clinical trials. Recently, the application of paediatric-inspired treatment protocols extends to adolescents and young adults (AYA) up to 30–40 years of age. The treatment outcome in AYA also demonstrated improved survival outcome to 60–70%. The more intensive chemotherapy regimens adopted in paediatrics are associated with more side effects and complications in AYA as compared to children. Guidelines on management of intensive chemotherapy protocols will help to reduce severe complications and improve compliance to treatment, thus improves the outcome. With the success of chemotherapy treatment, allogeneic haematopoietic stem cell transplant (HSCT) may not be required for most of the AYA with ALL, but reserved for very high-risk ALL or relapsed ALL.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 169.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Hardcover Book
USD 219.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Howlader N NA, Krapcho M, Miller D, Brest A, Yu M, Ruhl J, Tatalovich Z, et al. SEER Cancer Statistics Review 1975-2018. National Cancer Institute 2021.

    Google Scholar 

  2. Feng J, Cheng FWT, Chiang AKS, Lam GKS, Chow TTW, Ha SY, et al. Outcomes of adolescents with acute lymphoblastic leukaemia. Hong Kong Med J. 2022;28:204–14.

    PubMed  Google Scholar 

  3. Tasian SK, Loh ML, Hunger SP. Philadelphia chromosome-like acute lymphoblastic leukemia. Blood. 2017;130:2064–72.

    Article  PubMed  PubMed Central  Google Scholar 

  4. NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for Acute Lymphoblastic Leukemia Version 1.2022 (April 4, 2022). https://www.nccn.org/professionals/physician_gls/pdf/all.pdf

  5. Toft N, Birgens H, Abrahamsson J, Griškevičius L, Hallböök H, Heyman M, et al. Results of NOPHO ALL2008 treatment for patients aged 1–45 years with acute lymphoblastic leukemia. Leukemia. 2018;32:606–15.

    Article  PubMed  Google Scholar 

  6. Jain N, Lamb AV, O'Brien S, Ravandi F, Konopleva M, Jabbour E, et al. Early T-cell precursor acute lymphoblastic leukemia/lymphoma (ETP-ALL/LBL) in adolescents and adults: a high-risk subtype. Blood. 2016;127:1863–9.

    Article  PubMed  PubMed Central  Google Scholar 

  7. Svaton M, Skotnicova A, Reznickova L, Rennerova A, Valova T, Kotrova M, et al. NGS better discriminates true MRD positivity for the risk stratification of childhood ALL treated on MRD-based protocol. Blood:2022017003. https://doi.org/10.1182/blood.2022017003.

  8. Kantarjian H, Thomas D, O'Brien S, Cortes J, Giles F, Jeha S, et al. Long-term follow-up results of hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone (Hyper-CVAD), a dose-intensive regimen, in adult acute lymphocytic leukemia. Cancer. 2004;101:2788–801.

    Article  PubMed  Google Scholar 

  9. Thomas DA, O'Brien S, Faderl S, Garcia-Manero G, Ferrajoli A, Wierda W, et al. Chemoimmunotherapy with a modified hyper-CVAD and rituximab regimen improves outcome in de novo Philadelphia chromosome-negative precursor B-lineage acute lymphoblastic leukemia. J Clin Oncol. 2010;28:3880–9.

    Article  PubMed  PubMed Central  Google Scholar 

  10. Testi AM, Attarbaschi A, Valsecchi MG, Möricke A, Cario G, Niggli F, et al. Outcome of adolescent patients with acute lymphoblastic leukaemia aged 10-14 years as compared with those aged 15-17 years: long-term results of 1094 patients of the AIEOP-BFM ALL 2000 study. Eur J Cancer. 2019;122:61–71.

    Article  PubMed  Google Scholar 

  11. Burke MJ, Devidas M, Chen Z, Salzer WL, Raetz EA, Rabin KR, et al. Outcomes in adolescent and young adult patients (16 to 30 years) compared to younger patients treated for high-risk B-lymphoblastic leukemia: report from Children’s Oncology Group Study AALL0232. Leukemia. 2022;36:648–55.

    Article  PubMed  Google Scholar 

  12. Stock W, Luger SM, Advani AS, Yin J, Harvey RC, Mullighan CG, et al. A pediatric regimen for older adolescents and young adults with acute lymphoblastic leukemia: results of CALGB 10403. Blood. 2019;133:1548–59.

    Article  PubMed  PubMed Central  Google Scholar 

  13. Hough R, Rowntree C, Goulden N, Mitchell C, Moorman A, Wade R, et al. Efficacy and toxicity of a paediatric protocol in teenagers and young adults with Philadelphia chromosome negative acute lymphoblastic leukaemia: results from UKALL 2003. Br J Haematol. 2016;172:439–51.

    Article  PubMed  Google Scholar 

  14. DeAngelo DJ, Stevenson KE, Dahlberg SE, Silverman LB, Couban S, Supko JG, et al. Long-term outcome of a pediatric-inspired regimen used for adults aged 18-50 years with newly diagnosed acute lymphoblastic leukemia. Leukemia. 2015;29:526–34.

    Article  PubMed  Google Scholar 

  15. Arico M, Schrappe M, Hunger SP, Carroll WL, Conter V, Galimberti S, et al. Clinical outcome of children with newly diagnosed Philadelphia chromosome-positive acute lymphoblastic leukemia treated between 1995 and 2005. J Clin Oncol. 2010;28:4755–61.

    Article  PubMed  PubMed Central  Google Scholar 

  16. Schultz KR, Carroll A, Heerema NA, Bowman WP, Aledo A, Slayton WB, et al. Long-term follow-up of imatinib in pediatric Philadelphia chromosome-positive acute lymphoblastic leukemia: Children's Oncology Group study AALL0031. Leukemia. 2014;28:1467–71.

    Article  PubMed  PubMed Central  Google Scholar 

  17. Biondi A, Schrappe M, De Lorenzo P, Castor A, Lucchini G, Gandemer V, et al. Imatinib after induction for treatment of children and adolescents with Philadelphia-chromosome positive acute lymphoblastic leukaemia (EsPhALL): a randomised, open label, intergroup study. Lancet Oncol. 2012;13:936–45.

    Article  PubMed  PubMed Central  Google Scholar 

  18. Slayton WB, Schultz KR, Kairalla JA, Devidas M, Mi X, Pulsipher MA, et al. Dasatinib plus intensive chemotherapy in children, adolescents, and young adults with Philadelphia chromosome-positive acute lymphoblastic leukemia: Results of Children’s Oncology Group Trial AALL0622. J Clin Oncol. 2018;36:2306–14.

    Article  PubMed  PubMed Central  Google Scholar 

  19. Shen S, Chen X, Cai J, Yu J, Gao J, Hu S, et al. Effect of dasatinib vs imatinib in the treatment of pediatric Philadelphia chromosome-positive acute lymphoblastic leukemia: a randomized clinical trial. JAMA Oncol. 2020; https://doi.org/10.1001/jamaoncol.2019.5868.

  20. Ravandi F, O'Brien S, Thomas D, Faderl S, Jones D, Garris R, et al. First report of phase 2 study of dasatinib with hyper-CVAD for the frontline treatment of patients with Philadelphia chromosome-positive (Ph+) acute lymphoblastic leukemia. Blood. 2010;116:2070–7.

    Article  PubMed  PubMed Central  Google Scholar 

  21. Bassan R, Rossi G, Pogliani EM, Di Bona E, Angelucci E, Cavattoni I, et al. Chemotherapy-phased imatinib pulses improve long-term outcome of adult patients with Philadelphia chromosome-positive acute lymphoblastic leukemia: Northern Italy Leukemia Group protocol 09/00. J Clin Oncol. 2010;28:3644–52.

    Article  PubMed  Google Scholar 

  22. Lew G, Chen Y, Lu X, Rheingold SR, Whitlock JA, Devidas M, et al. Outcomes after late bone marrow and very early central nervous system relapse of childhood B-acute lymphoblastic leukemia: a report from the Children’s Oncology Group phase III study AALL0433. Haematologica. 2021;106:46–55.

    Article  PubMed  Google Scholar 

  23. Fielding AK, Richards SM, Chopra R, Lazarus HM, Litzow MR, Buck G, et al. Outcome of 609 adults after relapse of acute lymphoblastic leukemia (ALL); an MRC UKALL12/ECOG 2993 study. Blood. 2007;109:944–50.

    Article  PubMed  Google Scholar 

  24. Oriol A, Vives S, Hernandez-Rivas JM, Tormo M, Heras I, Rivas C, et al. Outcome after relapse of acute lymphoblastic leukemia in adult patients included in four consecutive risk-adapted trials by the PETHEMA Study Group. Haematologica. 2010;95:589–96.

    Article  PubMed  PubMed Central  Google Scholar 

  25. Mohty M, Labopin M, Volin L, Gratwohl A, Socié G, Esteve J, Tabrizi R, et al. Reduced-intensity versus conventional myeloablative conditioning allogeneic stem cell transplantation for patients with acute lymphoblastic leukemia: a retrospective study from the European Group for Blood and Marrow Transplantation. Blood. 2010;116:4439–43.

    Article  PubMed  Google Scholar 

  26. Brown PA, Ji L, Xu X, Devidas M, Hogan LE, Borowitz MJ, et al. Effect of postreinduction therapy consolidation with blinatumomab vs chemotherapy on disease-free survival in children, adolescents, and young adults with first relapse of B-cell acute lymphoblastic leukemia: a randomized clinical trial. JAMA. 2021;325:833–42.

    Article  PubMed  PubMed Central  Google Scholar 

  27. Jabbour E, Ravandi F, Kebriaei P, Huang X, Short NJ, Thomas D, et al. Salvage chemoimmunotherapy with inotuzumab ozogamicin combined with minihyper-CVD for patients with relapsed or refractory Philadelphia chromosome-negative acute lymphoblastic leukemia: a phase 2 clinical trial. JAMA Oncol. 2018;4:230–4.

    Article  PubMed  Google Scholar 

  28. Jabbour E, Sasaki K, Ravandi F, Huang X, Short NJ, Khouri M, et al. Chemoimmunotherapy with inotuzumab ozogamicin combined with mini-hyper-CVD, with or without blinatumomab, is highly effective in patients with Philadelphia chromosome-negative acute lymphoblastic leukemia in first salvage. Cancer. 2018;124:4044–55.

    Article  PubMed  Google Scholar 

  29. DeAngelo DJ, Yu D, Johnson JL, Coutre SE, Stone RM, Stopeck AT, et al. Nelarabine induces complete remissions in adults with relapsed or refractory T-lineage acute lymphoblastic leukemia or lymphoblastic lymphoma: Cancer and Leukemia Group B study 19801. Blood. 2007;109:5136–42.

    Article  PubMed  PubMed Central  Google Scholar 

  30. Rives S, Maude SL, Hiramatsu H, Baruchel A, Bader P, Bittencourt H, et al. Tisagenlecleucel in pediatric and young adult patients (pts) with relapsed/refractory (r/r) b-cell acute lymphoblastic leukemia (B-ALL): final analyses from the EIANA study. European Hematology Association 2022 Congress, oral presentation S112.

    Google Scholar 

  31. Shah BD, Ghobadi A, Oluwole OO, Logan AC, Boissel N, Cassaday RD, et al. KTE-X19 for relapsed or refractory adult B-cell acute lymphoblastic leukaemia: phase 2 results of the single-arm, open-label, multicentre ZUMA-3 study. Lancet. 2021;398(10299):491–502.

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Paediatrics, The Chinese University of Hong Kong, New Territories, Hong Kong

    Chi-Kong Li

  2. Department of Paediatrics & Adolescent Medicine, The Hong Kong Children’s Hospital, Kowloon, Hong Kong

    Frankie Wai-Tsoi Cheng & Daniel Ka-Leung Cheuk

Authors
  1. Chi-Kong Li
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Frankie Wai-Tsoi Cheng
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Daniel Ka-Leung Cheuk
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Chi-Kong Li .

Editor information

Editors and Affiliations

  1. Department of Medicine, Queen Mary Hospital, Hongkong, Hong Kong

    Harinder Gill

  2. Department of Medicine, Queen Mary Hospital, Hongkong, Hong Kong

    Yok-Lam Kwong

Rights and permissions

Reprints and permissions

Copyright information

© 2023 The Author(s), under exclusive license to Springer Nature Singapore Pte Ltd.

About this chapter

Check for updates. Verify currency and authenticity via CrossMark

Cite this chapter

Li, CK., Cheng, F.WT., Cheuk, D.KL. (2023). Management of Adolescent and Young Adults with Acute Lymphoblastic Leukaemia. In: Gill, H., Kwong, YL. (eds) Pathogenesis and Treatment of Leukemia. Springer, Singapore. https://doi.org/10.1007/978-981-99-3810-0_20

Download citation

  • DOI: https://doi.org/10.1007/978-981-99-3810-0_20

  • Published:

  • Publisher Name: Springer, Singapore

  • Print ISBN: 978-981-99-3809-4

  • Online ISBN: 978-981-99-3810-0

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation